Bracco is consolidating operations in China. A production plant of Bracco-SINE Pharmaceutical, the joint venture formed by the Italian group with one of China's primary pharmaceuticals companies, is opening in Pudong (Shanghai). The new plant, which
Bracco is consolidating operations in China. A production plant of Bracco-SINE Pharmaceutical, the joint venture formed by the Italian group with one of China's primary pharmaceuticals companies, is opening in Pudong (Shanghai). The new plant, which covers 2000 square meters, will produce contrast media for diagnostic imaging systems. It focuses on the final cycle in contrast media production. Basic substances sent from Italy are processed into solutions, then prepared, sealed, and sterilized into injectible products. The market for contrast media is expected to rise in China by an annual 20% to 30%.
Canadian software developer Cedara has opened a new office in Shanghai. The company's PACS products are already being sold by some of the country's leading medical equipment manufacturers. Cedara's new Chinese office is another step toward establishing a larger presence in the region, according to the company. The Shanghai office will provide local sales, support, and training to the company's Chinese customer base, as well as to customers in the Asia-Pacific region.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.